ADMA Biologics Shares Owned By Institutions vs. Price To Book

ADMA Stock  USD 21.47  0.29  1.37%   
Based on ADMA Biologics' profitability indicators, ADMA Biologics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess ADMA Biologics' ability to earn profits and add value for shareholders. At present, ADMA Biologics' Days Sales Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Operating Cash Flow Sales Ratio is expected to grow to 0.04, whereas Price To Sales Ratio is forecasted to decline to 3.72. At present, ADMA Biologics' Operating Income is projected to decrease significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 1.1 M, whereas Income Before Tax is forecasted to decline to (29.7 M).
For ADMA Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ADMA Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ADMA Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ADMA Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ADMA Biologics over time as well as its relative position and ranking within its peers.
  

ADMA Biologics' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
14
Earnings Share
0.27
Revenue Per Share
1.661
Quarterly Revenue Growth
0.781
Return On Assets
0.1989
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ADMA Biologics Price To Book vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ADMA Biologics's current stock value. Our valuation model uses many indicators to compare ADMA Biologics value to that of its competitors to determine the firm's financial worth.
ADMA Biologics is rated below average in shares owned by institutions category among its peers. It is rated second in price to book category among its peers fabricating about  0.24  of Price To Book per Shares Owned By Institutions. The ratio of Shares Owned By Institutions to Price To Book for ADMA Biologics is roughly  4.21 . The current year's Price To Book Ratio is expected to grow to 7.86. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADMA Biologics' earnings, one of the primary drivers of an investment's value.

ADMA Biologics' Earnings Breakdown by Geography

ADMA Price To Book vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

ADMA Biologics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
90.91 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

ADMA Biologics

P/B

 = 

MV Per Share

BV Per Share

 = 
21.59 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

ADMA Price To Book Comparison

ADMA Biologics is currently under evaluation in price to book category among its peers.

ADMA Biologics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ADMA Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ADMA Biologics will eventually generate negative long term returns. The profitability progress is the general direction of ADMA Biologics' change in net profit over the period of time. It can combine multiple indicators of ADMA Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income21.6 M22.7 M
Income Before Tax-28.2 M-29.7 M
Net Loss-28.2 M-29.7 M
Total Other Income Expense Net-49.9 M-47.4 M
Income Tax Expense8.2 M5.9 M
Net Loss-22.8 M-24 M
Non Operating Income Net Other-6.5 M-6.2 M
Net Loss-59.3 M-62.3 M
Interest IncomeM1.1 M
Net Interest Income-23.5 M-22.4 M
Change To Netincome17.6 M18.5 M
Net Loss(0.13)(0.13)
Income Quality(0.31)(0.30)
Net Income Per E B T 1.16  0.90 

ADMA Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ADMA Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ADMA Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ADMA Biologics' important profitability drivers and their relationship over time.

Use ADMA Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADMA Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADMA Biologics will appreciate offsetting losses from the drop in the long position's value.

ADMA Biologics Pair Trading

ADMA Biologics Pair Trading Analysis

The ability to find closely correlated positions to ADMA Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADMA Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADMA Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADMA Biologics to buy it.
The correlation of ADMA Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADMA Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADMA Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ADMA Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ADMA Biologics position

In addition to having ADMA Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Banks - Regional Thematic Idea Now

Banks - Regional
Banks - Regional Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banks - Regional theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks - Regional Theme or any other thematic opportunities.
View All  Next Launch
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:
Check out Trending Equities.
For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
To fully project ADMA Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ADMA Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ADMA Biologics' income statement, its balance sheet, and the statement of cash flows.
Potential ADMA Biologics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ADMA Biologics investors may work on each financial statement separately, they are all related. The changes in ADMA Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ADMA Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.